Full Breakdown
Foundayo Launch Marks First European Availability of an Oral GLP-1 Weight-Loss Pill
8/25/2026, 6:11:30 AM
Background & Context
Orforglipron, marketed as Foundayo, is Eli Lilly’s oral glucagon-like peptide-1 (GLP-1) medication that treats type 2 diabetes and supports weight loss. It follows Novo Nordisk’s Wegovy tablet, the first GLP-1 pill approved in the United Kingdom on 11 June. The UK became the first European nation to authorize an oral GLP-1 for both indications when the Medicines and Healthcare products Regulatory Agency (MHRA) granted approval on 10 August.
Timeline
- 10 August – MHRA authorises Foundayo for adults with a BMI >= 30, or BMI 27-30 with a weight-related condition, and for poorly controlled type 2 diabetes.
- Later in August – Eli Lilly announces private-prescription availability of Foundayo in UK pharmacies.
- 18 November – NICE is scheduled to issue its appraisal of Foundayo for obesity treatment, determining NHS funding.
Pricing and Market Position
Foundayo is priced at £100 – £120 per month on the private market, lower than Lilly’s injectable Mounjaro (£330 per month) and comparable to the Wegovy tablet (£74 – £129 for initial doses). The cash price is intended to broaden access, but the drug remains prescription-only and is not yet covered by the NHS pending the NICE review.
Official Statements & Responses
- Khalil Asmar, vice-president of cardiometabolic health at Lilly Northern Europe, called the launch a milestone for oral treatment options.
- Henry Gregg, chief executive of the National Pharmacy Association, said the day was “significant” for patients who cannot or prefer not to use injections.
- Dr Neelam Bains, GP at LloydsPharmacy Online Doctor, urged patients to obtain the medication only through registered pharmacies and qualified clinicians.
Criticism & Opposition
Pharmacists warned that pill formulations are easier to counterfeit than injectables. The MHRA seized £250,000 worth of unlicensed weight-loss pens and ingredients from a Northampton factory last year, and Lilly is pursuing legal action against suppliers it alleges operate an illegal secondary market. The National Pharmacy Association also described the current NHS weight-management system as a “postcode lottery,” noting wide variation in access.
Verbatim Quotes
- “The UK is the first country in Europe where Foundayo is now available,” — Khalil Asmar, Lilly Northern Europe
- “Always check any pharmacy is registered with the General Pharmaceutical Council and if a website is offering these medications without asking about your medical history, requiring a prescription – or at a price that seems too good to be true – do not buy them.” — Dr Neelam Bains, LloydsPharmacy Online Doctor
What’s Next
NICE’s appraisal, due on 18 November, will assess Foundayo’s clinical and cost effectiveness for obesity treatment. A positive recommendation could lead to NHS funding, but until then the drug remains available only via private prescription, leaving many patients to navigate a fragmented access landscape.
